Patents Assigned to ORADIN PHARMACEUTICAL LTD.
  • Adenosine A3 receptor antagonists for treating aging skin and wounds
    Patent number: 12233053
    Abstract: The invention provides a method of improving the appearance of aging skin by administering locally to an area of the aging skin of a subject a cosmetic or dermatological composition that includes an effective amount of an adensoine A3 receptor antagonist and a dermatologically acceptable carrier, thereby improving the appearance of the area of the aging skin.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: February 25, 2025
    Assignee: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana Madi, Rafi Korenstein
  • ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING AGING SKIN AND WOUNDS
    Publication number: 20240216351
    Abstract: The invention provides a method of improving the appearance of aging skin by administering locally to an area of the aging skin of a subject a cosmetic or dermatological composition that includes an effective amount of an adensoine A3 receptor antagonist and a dermatologically acceptable carrier, thereby improving the appearance of the area of the aging skin.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 4, 2024
    Applicant: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana MADI, Rafi KORENSTEIN
  • A3 adenosine receptor ligands for modulation of pigmentation
    Patent number: 9668959
    Abstract: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: June 6, 2017
    Assignee: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana Madi, Rafi Korenstein
  • A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION
    Publication number: 20160136079
    Abstract: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 19, 2016
    Applicant: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana MADI, Rafi KORENSTEIN
  • A3 adenosine receptor ligands for modulation of pigmentation
    Patent number: 9199102
    Abstract: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: December 1, 2015
    Assignee: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana Madi, Rafi Korenstein
  • A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION
    Publication number: 20120134945
    Abstract: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.
    Type: Application
    Filed: July 20, 2010
    Publication date: May 31, 2012
    Applicant: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana Madi, Rafi Korenstein